title: A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.
abstract: Radium-223 dichloride is an alpha-emitting radiopharmaceutical which significantly prolongs overall survival in patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases. This was a retrospective analysis of the efficacy and safety of Radium-223 in the first 41 patients treated at a single center in Hungary. Radium-223 was given at a dose of 50 kBq/kg intravenously every 4 weeks for up to 6 cycles. Between 23rd July 2014 and 23rd February 2016, 41 patients were treated. Patient demographics, laboratory values, treatment outcomes and adverse events were collected from medical records. The mean age was 72.2 years (SD: 7.1). 24 patients received Radium-223 as first-line treatment (58%), 7 patients as second (17%), 3 as third (7.3%), 6 as (14.6%), and 1 as fifth-line therapy (2.4%). The mean number of cycles administered was 5.5 (SD: 1.1). The most common side effects were anemia (32% grade 1-3), nausea (28%, grade 1), diarrhea (4%, grade 2), thrombocytopenia (4%, grade 3). The mean baseline PSA level was 307.2 ng/ml (SD: 525.7), which increased to a mean value of 728.5 ng/ml (SD: 1277) by the end of treatment. The baseline mean ALP of 521.1 U/L (SD: 728) decreased to 245.1 U/L (SD: 283.5). The majority of patients experienced a decrease (37%) or complete cessation (43%) of bone pain intensity. In our symptomatic prostate cancer patient population, Radium-223 proved to be efficient in terms of pain relief, with moderate side effects. No PSA response was detected, while alkaline phosphatase levels significantly decreased.
authors.affiliation: National Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary. kuronyaz@gmail.com.
authors.forename: Zs
authors.identifier: http://orcid.org/0000-0001-8500-5924
authors.initials: Z
authors.lastname: Küronya
authors.affiliation: National Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
authors.forename: I
authors.initials: I
authors.lastname: Sinkovics
authors.affiliation: National Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
authors.forename: P
authors.initials: P
authors.lastname: Ágoston
authors.affiliation: National Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
authors.forename: K
authors.initials: K
authors.lastname: Bíró
authors.affiliation: National Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
authors.forename: I
authors.initials: I
authors.lastname: Bodrogi
authors.affiliation: Jahn Ferenc South-Pest Hospital, Budapest, Hungary.
authors.forename: I
authors.initials: I
authors.lastname: Böde
authors.affiliation: 1st Department of Internal Medicine, Semmelweis University, Budapest, Hungary.
authors.forename: M
authors.initials: M
authors.lastname: Dank
authors.affiliation: National Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
authors.forename: F
authors.initials: F
authors.lastname: Gyergyay
authors.affiliation: National Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
authors.forename: T
authors.initials: T
authors.lastname: Vajdics
authors.affiliation: Teaching Hospital Mór Kaposi, Kaposvár, Hungary.
authors.forename: Zs
authors.initials: Z
authors.lastname: Kolonics
authors.affiliation: National Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
authors.forename: K
authors.initials: K
authors.lastname: Nagyiványi
authors.affiliation: Teaching Hospital Mór Kaposi, Kaposvár, Hungary.
authors.forename: Á
authors.initials: Á
authors.lastname: Rúzsa
authors.affiliation: National Institute of Oncology, Ráth György u. 7-9, Budapest, H-1122, Hungary.
authors.forename: L
authors.initials: L
authors.lastname: Géczi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D000072716:Cancer Pain / Q000532:radiotherapy*; D006801:Humans; D006814:Hungary; D008297:Male; D008875:Middle Aged; D064129:Prostatic Neoplasms, Castration-Resistant / Q000532:radiotherapy* / Q000556:secondary; D011868:Radioisotopes / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D011883:Radium / Q000627:therapeutic use*; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D011868:Radioisotopes; D019275:Radiopharmaceuticals; C581106:radium Ra 223 dichloride; D011883:Radium
keywords: Bone pain; Metastatic castration-resistant prostate cancer (mCRPC); Radium-223